Acurx Pharmaceuticals, Inc. (ACXP)Healthcare | Biotechnology | Staten Island, United States | NasdaqCM
2.38 USD
-0.11
(-4.418%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 2.48 +0.10 (4.202%) ⇧ (April 17, 2026, 7:58 p.m. EDT) Short-term: ★☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 1:09 p.m. EDT
ACXP is currently experiencing significant volatility, with a sharp decline in price over the past few weeks, indicating a lack of momentum and potential short-term risks. The stock has a negative beta, suggesting it moves inversely to the market, which could be a factor for short-term traders looking to capitalize on dips. However, the recent price history shows a downward trend, and the low volume compared to the average indicates weak buying pressure. The stock has a poor financial outlook with negative earnings and return metrics, which makes it unsuitable for long-term investment. There are no dividend payouts, so it's not a good choice for income-focused investors. Overall, the stock appears to be a high-risk, low-reward opportunity, and investors should proceed with caution. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.353788 |
| AutoARIMA | 0.355909 |
| AutoETS | 0.355909 |
| AutoTheta | 0.517143 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.91 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.280 |
| Excess Kurtosis | -1.03 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 6,794,960 |
| Forward P/E | -1.08 |
| Beta | -1.92 |
| Previous Name | Acurx Pharmaceuticals, LLC |
| Website | https://www.acurxpharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.6626016 |
| Address1 | 259 Liberty Avenue |
| All Time High | 176.4 |
| All Time Low | 1.326 |
| Ask | 2.44 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 190,570 |
| Average Daily Volume3 Month | 3,159,077 |
| Average Volume | 3,159,077 |
| Average Volume10Days | 190,570 |
| Beta | -1.919 |
| Bid | 2.31 |
| Bid Size | 1 |
| Book Value | 2.244 |
| City | Staten Island |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.38 |
| Current Ratio | 3.176 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 2.65 |
| Day Low | 2.34 |
| Display Name | Acurx Pharmaceuticals |
| Earnings Call Timestamp End | 1,773,403,200 |
| Earnings Call Timestamp Start | 1,773,403,200 |
| Earnings Timestamp | 1,773,405,000 |
| Earnings Timestamp End | 1,778,675,400 |
| Earnings Timestamp Start | 1,778,675,400 |
| Ebitda Margins | 0.0 |
| Enterprise Value | -761,140 |
| Eps Current Year | -2.39 |
| Eps Forward | -2.2 |
| Eps Trailing Twelve Months | -5.32 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.955 |
| Fifty Day Average Change | -0.5749998 |
| Fifty Day Average Change Percent | -0.19458538 |
| Fifty Two Week Change Percent | -66.26016 |
| Fifty Two Week High | 21.0 |
| Fifty Two Week High Change | -18.619999 |
| Fifty Two Week High Change Percent | -0.8866666 |
| Fifty Two Week Low | 1.326 |
| Fifty Two Week Low Change | 1.0540001 |
| Fifty Two Week Low Change Percent | 0.7948719 |
| Fifty Two Week Range | 1.326 - 21.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,624,627,800,000 |
| Float Shares | 2,726,406 |
| Forward Eps | -2.2 |
| Forward P E | -1.0818182 |
| Free Cashflow | -4,291,853 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 4 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04504 |
| Held Percent Institutions | 0.078150004 |
| Implied Shares Outstanding | 2,855,025 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-06-25 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,754,352,000 |
| Last Split Factor | 1:20 |
| Long Business Summary | Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York. |
| Long Name | Acurx Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 6,794,960 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_558025934 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-16 |
| Net Income To Common | -7,966,538 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 7,109,012 |
| Number Of Analyst Opinions | 3 |
| Open | 2.59 |
| Operating Cashflow | -6,787,782 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 917 533 1469 |
| Post Market Change | 0.099999905 |
| Post Market Change Percent | 4.2016764 |
| Post Market Price | 2.48 |
| Post Market Time | 1,776,470,330 |
| Prev Name | Acurx Pharmaceuticals, LLC |
| Previous Close | 2.49 |
| Price Eps Current Year | -0.99581593 |
| Price Hint | 4 |
| Price To Book | 1.0606061 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.141 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.11 |
| Regular Market Change Percent | -4.41767 |
| Regular Market Day High | 2.65 |
| Regular Market Day Low | 2.34 |
| Regular Market Day Range | 2.34 - 2.65 |
| Regular Market Open | 2.59 |
| Regular Market Previous Close | 2.49 |
| Regular Market Price | 2.38 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 195,560 |
| Return On Assets | -0.87595004 |
| Return On Equity | -2.708 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 2,855,025 |
| Shares Percent Shares Out | 0.0358 |
| Shares Short | 102,286 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 57,707 |
| Short Name | Acurx Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.0376 |
| Short Ratio | 0.01 |
| Source Interval | 15 |
| State | NY |
| Symbol | ACXP |
| Target High Price | 31.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 17.0 |
| Target Median Price | 10.0 |
| Total Cash | 7,556,100 |
| Total Cash Per Share | 2.647 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -5.32 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.49759 |
| Two Hundred Day Average Change | -2.11759 |
| Two Hundred Day Average Change Percent | -0.4708277 |
| Type Disp | Equity |
| Volume | 195,560 |
| Website | https://www.acurxpharma.com |
| Zip | 10,305 |